08:00 AM EDT, 08/22/2024 (MT Newswires) -- Merck & Company ( MRK ) said Thursday Health Canada has approved the use of KEYTRUDA in combination with enfortumab vedotin to treat adults with urothelial cancer.

The approval is based on results from the phase 3 trial of the drug, which showed statistically significant improvements in overall survival and progression-free survival compared with chemotherapy, the company said.

Price: 116.20, Change: +0.17, Percent Change: +0.15